Spiro Medical

Executive Summary

Spiro Medical, a San Francisco-based private medical device company founded in 2017, is developing the Spiro Neuromodulation System, a novel drug-free therapy for severe chronic airway diseases including asthma, chronic cough, and COPD. The system leverages neuromodulation to target the neural pathways driving airway hyperreactivity and inflammation, offering a potential alternative to chronic pharmaceutical use. With a mission to enable patients to breathe freely without reliance on drugs, Spiro addresses a significant unmet need in respiratory care. The company's approach could improve quality of life and reduce the burden of daily medication for millions of patients worldwide. While still in early development stages, the technology represents a paradigm shift in the treatment of airway diseases, moving beyond symptomatic management toward a neuromodulatory intervention. Spiro Medical has not disclosed funding, valuation, or clinical milestones, indicating a pre-revenue, preclinical or early clinical stage. Given the rise of neuromodulation in various therapeutic areas and the large global markets for asthma and COPD, Spiro's platform holds substantial promise. However, the lack of public data and the inherent risks of early-stage device development warrant a cautious but optimistic outlook.

Upcoming Catalysts (preview)

• Q3 2026FDA Breakthrough Device Designation60% success
• Q4 2026First-in-Human Study Results40% success
• Q1 2027Series A Financing Announcement50% success